Abstract
Objectives: Dilated cardiomyopathy (DCM) is a leading cause of sudden cardiac death. So far, only 127 mutations of Titin(TTN) have been reported in patients with different phenotypes such as isolated cardiomyopathies, purely skeletal muscle phenotypes or complex overlapping disorders of muscles. Methods: We applied whole-exome sequencing (WES) to investigate cardiomyopathy patients and a cardiomyopathy-related gene-filtering strategy was used to analyze the disease-causing mutations. Sanger sequencing was applied to confirm the mutation cosegregation in the affected families. Results: A nonsense mutation (c.12325C>T/p.R4109X) and a missense mutation (c.17755G>C/p.G5919R) of TTN were identified in 2 Chinese DCM families, respectively. Both mutations were cosegregated in all affected members of both families. The nonsense mutation is predicted to result in a truncated TTN protein and the missense mutation leads to a substitution of glycine by arginine. Both variants may cause the structure changes of titin protein. Conclusions: We employed WES to detect the mutations of DCM patients and identified 2 novel mutations. Our study expands the spectrum of TTN mutations and offers accurate genetic testing information for DCM patients who are still clinically negative.
Journal Section:
Short Communication
References
1.
Hershberger RE, Hedges DJ, Morales A: Dilated cardiomyopathy: the complexity of a diverse genetic architecture. Nat Rev Cardiol 2013;10:531-547.
[PubMed]
2.
McNally EM, Golbus JR, Puckelwartz MJ: Genetic mutations and mechanisms in dilated cardiomyopathy. J Clin Invest 2013;123:19-26.
[PubMed]
3.
Kimura A: Molecular genetics and pathogenesis of cardiomyopathy. J Hum Genet 2016;61:41-50.
[PubMed]
4.
van Spaendonck-Zwarts KY, Posafalvi A, van den Berg MP, Hilfiker-Kleiner D, Bollen IA, Sliwa K, Alders M, Almomani R, van Langen IM, van der Meer P, Sinke RJ, van der Velden J, Van Veldhuisen DJ, van Tintelen JP, Jongbloed JD: Titin gene mutations are common in families with both peripartum cardiomyopathy and dilated cardiomyopathy. Eur Heart J 2014;35:2165-2173.
[PubMed]
5.
Chauveau C, Rowell J, Ferreiro A: A rising Titan: TTN review and mutation update. Hum Mutat 2014;35:1046-1059.
[PubMed]
6.
Yue D, Gao M, Zhu W, Luo S, Xi J, Wang B, Li Y, Cai S, Li J, Wang Y, Lu J, Zhao C: New disease allele and de novo mutation indicate mutational vulnerability of titin exon 343 in hereditary myopathy with early respiratory failure. Neuromuscul Disord 2015;25:172-176.
[PubMed]
7.
Peled Y, Gramlich M, Yoskovitz G, Feinberg MS, Afek A, Polak-Charcon S, Pras E, Sela BA, Konen E, Weissbrod O, Geiger D, Gordon PM, Thierfelder L, Freimark D, Gerull B, Arad M: Titin mutation in familial restrictive cardiomyopathy. Int J Cardiol 2014;171:24-30.
[PubMed]
8.
Gerull B: The rapidly evolving role of titin in cardiac physiology and cardiomyopathy. Can J Cardiol 2015;31:1351-1359.
[PubMed]
9.
Xiang R, Fan LL, Huang H, Zhao SP, Chen YQ: Whole-exome sequencing identifies a novel mutation of DSG2 (Y198C) in a Chinese arrhythmogenic right ventricular cardiomyopathy patient. Int J Cardiol 2016;214:1-3.
[PubMed]
10.
Tan ZP, Xie L, Deng Y, Chen JL, Zhang WZ, Wang J, Yang JF, Yang YF: Whole-exome sequencing identifies Y1495X of SCN5A to be associated with familial conduction disease and sudden death. Sci Rep 2014;4:5616.
[PubMed]
11.
Lange S, Xiang F, Yakovenko A, Vihola A, Hackman P, Rostkova E, Kristensen J, Brandmeier B, Franzen G, Hedberg B, Gunnarsson LG, Hughes SM, Marchand S, Sejersen T, Richard I, Edstrom L, Ehler E, Udd B, Gautel M: The kinase domain of titin controls muscle gene expression and protein turnover. Science 2005;308:1599-1603.
[PubMed]
12.
Vikhlyantsev IM, Podlubnaya ZA: New titin (connectin) isoforms and their functional role in striated muscles of mammals: Facts and suppositions. Biochemistry Biokhimiia 2012;77:1515-1535.
[PubMed]
13.
Laure L, Daniele N, Suel L, Marchand S, Aubert S, Bourg N, Roudaut C, Duguez S, Bartoli M, Richard I: A new pathway encompassing calpain 3 and its newly identified substrate cardiac ankyrin repeat protein is involved in the regulation of the nuclear factor-κB pathway in skeletal muscle. FEBS J 2010;277:4322-4337.
[PubMed]
14.
Sauer F, Vahokoski J, Song YH, Wilmanns M: Molecular basis of the head-to-tail assembly of giant muscle proteins obscurin-like 1 and titin. EMBO Rep 2010;11:534-540.
[PubMed]
15.
Hedberg C, Toledo AG, Gustafsson CM, Larson G, Oldfors A, Macao B: Hereditary myopathy with early respiratory failure is associated with misfolding of the titin fibronectin III 119 subdomain. Neuromuscul Disord 2014;24:373-379.
[PubMed]
16.
Huebsch KA, Kudryashova E, Wooley CM, Sher RB, Seburn KL, Spencer MJ, Cox GA: Mdm muscular dystrophy: interactions with calpain 3 and a novel functional role for titin's N2A domain. Hum Mol Genet 2005;14:2801-2811.
[PubMed]
17.
Charton K, Daniele N, Vihola A, Roudaut C, Gicquel E, Monjaret F, Tarrade A, Sarparanta J, Udd B, Richard I: Removal of the calpain 3 protease reverses the myopathology in a mouse model for titinopathies. Hum Mol Genet 2010;19:4608-4624.
[PubMed]
18.
Yan L, Yang M, Guo H, Yang L, Wu J, Li R, Liu P, Lian Y, Zheng X, Yan J, Huang J, Li M, Wu X, Wen L, Lao K, Li R, Qiao J, Tang F: Single-cell RNA-Seq profiling of human preimplantation embryos and embryonic stem cells. Nat Struct Mol Biol 2013;20:1131-1139.
[PubMed]
© 2016 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2016
You do not currently have access to this content.
